PharmaFocus Today – Page 9 – media

Juncell Therapeutics Submits Hong Kong Listing Application, with CITIC Securities as Sole Sponsor

Juncell Therapeutics has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities acting as its exclusive sponsor. Juncell Therapeutics is a biotechnology company dedicated to developing innovative cell therapies and novel drugs for solid tumors, focusing on creating immune cell therapies that are safer, more effective, more accessible, and more affordable. The company’s core product, GC101, is the world’s first tumor-infiltrating lymphocyte (TIL) therapy that does not require high-intensity lymphodepleting chemotherapy or IL-2 administration. It is expected to become the first TIL therapy approved for marketing in China. As a single-dose treatment, TIL cell therapy has the potential to deliver curative outcomes for certain patients with advanced tumors. Clinical data show that TIL therapy also provides long-term benefits to patients with various types of solid tumors, including advanced melanoma, non-small cell lung cancer (NSCLC), and breast cancer. In Phase I clinical trials for advanced metastatic solid ...
- Source: drugdu
- 53
- December 11, 2025
Investee Subsidiary Enters Licensing Agreement with Pfizer for Innovative Metabolic Drug, with Total Potential Value up to $350 Million

Shanghai Securities News, China Securities Network – Chongqing Pharmaceutical Holdings announced on the evening of December 10 that its investee subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd. (referred to as “Yaoyou Pharmaceutical”), together with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., signed a Collaboration and License Agreement (referred to as the “License Agreement”) with Pfizer on December 9. Under the agreement, Yaoyou Pharmaceutical grants Pfizer exclusive rights for the development, use, production, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists (including YP05002) and products containing this active ingredient within the licensed territory (i.e., globally) and field (covering treatment, diagnosis, and prevention for all human and animal indications). For this license, Yaoyou Pharmaceutical is entitled to receive a non-refundable upfront payment of $150 million and up to $350 million in development milestone payments based on the clinical and commercial progress of the licensed product. It is reported that YP05002 is ...
- Source: drugdu
- 60
- December 11, 2025
We have obtained approval for a Phase I/II clinical trial of JS207 and JS212 for combined use

On December 10, TopAlliance Biosciences, in answering an investor question on an interactive platform, stated that the company has obtained approval for a Phase I/II clinical trial of combined use of JS207 (PD-1/VEGF bispecific antibody) and JS212 (EGFR/HER3 bispecific ADC), and plans to launch related clinical studies in the near future. JS207 is currently in the Phase II clinical study stage. Combination explorations are underway in multiple tumor types, combining JS207 with various drugs such as chemotherapy, monoclonal antibodies, and ADCs. The company will actively explore a variety of combination regimens to maximize the synergistic effect of its pipeline. It is noted that due to the early-stage research and development of pharmaceutical products and the lengthy, multi-stage cycle from R&D and clinical trial application to production, they are susceptible to various uncertainties. https://finance.eastmoney.com/a/202512103587875995.html
- Source: drugdu
- 58
- December 11, 2025
Expedite the review and approval of urgently needed new drugs, rare disease drugs, and pediatric medicines from overseas

Li Li, Secretary of the Party Leadership Group and Director of the National Medical Products Administration (NMPA), stated in an interview that pharmaceutical regulation work is closely related to people’s livelihoods. During the 15th Five-Year Plan period, pharmaceutical regulation will consistently regard enhancing the public’s sense of gain, happiness, and security as its fundamental starting point and ultimate goal. The aim is to ensure that the achievements of reform and development benefit the entire population more extensively and fairly, and to continuously meet the people’s aspirations for a better life and their needs for health protection. The NMPA will make full use of accelerated pathways, such as breakthrough therapy designation, conditional approval, priority review and approval, and special approval procedures. This will expedite the review and approval of urgently needed overseas new drugs, rare disease drugs, and pediatric medicines, shortening the distance from laboratory to bedside and allowing innovative achievements ...
- Source: drugdu
- 46
- December 11, 2025
How to Use B2B Platforms to Expand Global Sales Channels

As global pharmaceutical markets place increasing demands on the variety, quality and compliance of excipients, more and more excipient manufacturers are looking to move beyond their domestic markets and enter the international arena. However, the reality often looks like this: Overseas customers simply cannot find you Building your own international sales team is costly and time-consuming Lack of experience in registration and professional presentation makes it hard to build trust This article focuses on how excipient manufacturers can leverage B2B platforms to expand globally, and aims to provide small and medium-sized companies with a practical, repeatable and cost-controllable approach. I. Typical Challenges for Excipient Manufacturers Going Global 1. Single-channel dependence: heavily reliant on offline and personal networks Most companies still rely on a traditional mix of: “Domestic pharma exhibitions + trading companies + personal connections” This model is low in efficiency and makes it difficult to build a scalable and ...
- Source: drugdu
- 60
- December 10, 2025
WHO releases guidelines for the use of new weight-loss drugs

In response to the growing global challenge of obesity, the World Health Organization recently released its first global guideline　　on the use of glucagon-like peptide-1 (GLP-1) drugs for the treatment of obesity.Three drugs used to treat obesity in adults: liraglutide, smegglutide, and telpoglutide. The World Health Organization (WHO) defines obesity as an adult body mass index (BMI) of 30 or higher. According to WHO data, obesity is a chronic, relapsing disease, affecting more than one billion people globally. Obesity-related deaths reached 3.7 million in 2024. Without decisive action, the number of obese individuals is projected to double by 2030. WHO Director-General Dr. Tedros Adhanom Ghebreyesus stated, “Obesity is a major global health challenge, and the WHO is committed to supporting countries and people worldwide in addressing it effectively and equitably. The new guidelines acknowledge that obesity is a chronic disease that can be treated with comprehensive, lifelong care. While medication alone ...
- Source: drugdu
- 66
- December 9, 2025
Grand Pharmaceutical’s Class 1 innovative traditional Chinese medicine drug GPN01360 has reached its clinical endpoint in the Phase II clinical trial in China

On December 8, Grand Pharmaceutical (00512) issued an announcement stating that the Group’s traditional Chinese medicine…Class 1 innovative drugsThe Phase II clinical trial of GPN01360 in China successfully met its clinical endpoint. This study enrolled 148 patients with depression, who received oral administration for 8 weeks. The primary assessment was the efficacy and safety of GPN01360 compared to placebo in treating depression. Results showed that the primary efficacy endpoint, the change from baseline on the Hamilton Depression Rating Scale (HAMD-17), was significantly different from placebo (P=0.0006<0.05). Secondary efficacy endpoints, such as the Montgomery-Asperger’s Depression Rating Scale (MADRS), also showed significant differences (P<0.05). Furthermore, GPN01360 demonstrated good safety and tolerability, with no significant toxic side effects observed. GPN01360 is a Class 1.1 innovative traditional Chinese medicine 　　for the treatment of depression . Its main ingredients include 12 herbs such as Bupleurum, Curcuma longa, and Citrus medica , which have the effects ...
- Source: drugdu
- 70
- December 9, 2025
Incyte Pharma Drug Shows Positive Effect in Treatment of a Certain Type of Blood Cancer

Incyte Pharma states new clinical data shows its monoclonal antibody drug INCA033989 can rapidly and significantly reduce spleen volume, alleviate associated symptoms, and improve anemia in patients with myelofibrosis who have a specific genetic mutation. The preliminary research results come from treating patients with CALR mutation (mutCALR) myelofibrosis with the drug as monotherapy and in combination with ruxolitinib. The drug demonstrated good safety, with no dose-limiting toxicities reported. Incyte Pharma plans to initiate a registration program for myelofibrosis treatment in 2026. https://finance.eastmoney.com/a/202512073584646874.html
- Source: drugdu
- 61
- December 9, 2025
Ophthalmic preparation GB10 injection receives clinical trial approval notice

Securities Daily Online News On the evening of December 8th, Sinovac Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, Shenzhen Sinovac Pharmaceutical Co., Ltd., recently received a “Notice of Drug Clinical Trial Approval” from the National Medical Products Administration (NMPA). The NMPA has approved Shenzhen Sinovac to carry out clinical trials for the “GB10 Injection”. https://finance.eastmoney.com/a/202512083585556010.html
- Source: drugdu
- 60
- December 9, 2025
Huadong Medicine enters commercialization partnership with Sinorda Pharma

China Securities Journal, China Securities Network (Reporter Fu Suying) – On December 7, Huadong Medicine’s wholly-owned subsidiary Huadong Medicine (Hangzhou) Co., Ltd. announced that it has entered into an exclusive commercialization partnership for mainland China with Guizhou Sinorda Biotech Co., Ltd. and its wholly-owned subsidiaries Shanghai Sinorda Pharmaceutical Technology Co., Ltd. and Jiangsu Taris Sinorda Biopharmaceutical Co., Ltd. (collectively referred to as “Sinorda Pharma”). The partnership covers Sinorda’s product Linaprazan Glutarate Capsules and other dosage forms. Linaprazan is a next-generation potassium-competitive acid blocker (P-CAB) drug co-developed by Sinorda Pharma and Cinclus Pharma for the treatment of digestive system diseases. Leveraging Huadong Medicine’s strong commercialization platform, Linaprazan is expected to achieve rapid market uptake and will further enhance Huadong Medicine’s product portfolio in the digestive disease field. On December 7, the National Healthcare Security Administration disclosed that Linaprazan, indicated for gastroesophageal reflux disease, and the PARP inhibitor Senaparib (Paisuning®) have been ...
- Source: drugdu
- 59
- December 9, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.